- Home
- Publications
- Publication Search
- Publication Details
Title
Current Review on High-Risk Multiple Myeloma
Authors
Keywords
Multiple myeloma, High risk, <em class=EmphasisTypeItalic >t</em>(4;14), del(17p), Novel agents
Journal
Current Hematologic Malignancy Reports
Volume 12, Issue 2, Pages 96-108
Publisher
Springer Nature
Online
2017-03-20
DOI
10.1007/s11899-017-0368-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients
- (2016) Rafael Ríos-Tamayo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
- (2016) Rachid C. Baz et al. BLOOD
- Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
- (2016) B. Paiva et al. BLOOD
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Allogeneic stem cell transplantation for multiple myeloma: is there a future?
- (2016) B Dhakal et al. BONE MARROW TRANSPLANTATION
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
- (2016) O Landgren et al. BONE MARROW TRANSPLANTATION
- Singleversustandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial
- (2016) Elias K. Mai et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects
- (2016) Theodoros N. Sergentanis et al. Clinical Lymphoma Myeloma & Leukemia
- Revised International Staging System Applied to Real World Multiple Myeloma Patients
- (2016) Victor H. Jimenez-Zepeda et al. Clinical Lymphoma Myeloma & Leukemia
- Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
- (2016) N Majithia et al. LEUKEMIA
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma
- (2015) Moritz Binder et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
- (2015) X. Leleu et al. BLOOD
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
- (2015) B. Hebraud et al. BLOOD
- Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
- (2015) A. C. Rawstron et al. BLOOD
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
- (2015) M. A. Dimopoulos et al. HAEMATOLOGICA
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
- (2015) Francesca Gay et al. LANCET ONCOLOGY
- Defining and treating high-risk multiple myeloma
- (2015) S Z Usmani et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpretation of cytogenetic results in multiple myeloma for clinical practice
- (2015) A M Rajan et al. Blood Cancer Journal
- Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
- (2015) M. A. Dimopoulos et al. HAEMATOLOGICA
- Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
- (2014) W. I. Gonsalves et al. BLOOD
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents
- (2014) V H Jimenez-Zepeda et al. BONE MARROW TRANSPLANTATION
- Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
- (2014) Myungshin Kim et al. GENES CHROMOSOMES & CANCER
- Prognostic value of 1p deletion for multiple myeloma: a meta-analysis
- (2014) J. Ouyang et al. International Journal of Laboratory Hematology
- Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death
- (2014) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
- (2014) W I Gonsalves et al. LEUKEMIA
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
- (2013) G. Gahrton et al. BLOOD
- Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
- (2013) L. Pour et al. HAEMATOLOGICA
- Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
- (2013) C. Scheid et al. HAEMATOLOGICA
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
- (2013) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
- (2013) A J Greenberg et al. LEUKEMIA
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
- (2013) B Hebraud et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
- (2013) Joseph R. Mikhael et al. MAYO CLINIC PROCEEDINGS
- Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma
- (2012) Nicolaus Kröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
- (2012) S. Kumar et al. BLOOD
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
- (2012) L. Rosinol et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
- (2012) M. Cavo et al. BLOOD
- Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
- (2012) S. Z. Usmani et al. HAEMATOLOGICA
- Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
- (2012) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2012) Laurent Garderet et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
- (2012) H Avet-Loiseau et al. LEUKEMIA
- A gene expression signature for high-risk multiple myeloma
- (2012) R Kuiper et al. LEUKEMIA
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
- (2012) C Fernández de Larrea et al. LEUKEMIA
- Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
- (2012) Neil C. Dunavin et al. LEUKEMIA & LYMPHOMA
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
- (2012) A Kalff et al. Blood Cancer Journal
- Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
- (2011) S. K. Kumar et al. BLOOD
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
- (2011) Amrita Krishnan et al. LANCET ONCOLOGY
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
- (2011) K D Boyd et al. LEUKEMIA
- Clinical and biological features of t(4;14) multiple myeloma: a prospective study
- (2011) Lionel Karlin et al. LEUKEMIA & LYMPHOMA
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
- (2010) H. Avet-Loiseau et al. BLOOD
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
- (2010) N. J. Dickens et al. CLINICAL CANCER RESEARCH
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
- (2010) H Avet-Loiseau et al. LEUKEMIA
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
- (2009) S. Knop et al. BLOOD
- Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
- (2009) A. Kumar et al. JNCI-Journal of the National Cancer Institute
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
- (2009) E Kastritis et al. LEUKEMIA
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
- (2008) H. Ludwig et al. BLOOD
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
- (2008) J F San-Miguel et al. LEUKEMIA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started